Livzon Pharmaceutical Secures China Marketing Approval for Traditional Chinese Medicine

MT Newswires Live
10/27

Livzon Pharmaceutical Group (HKG:1513) said China's National Medical Products Administration approved its Wandai Tang Granules for marketing.

The traditional Chinese medicine is used to treat excessive vaginal discharge, according to a Tuesday Hong Kong bourse filings. Developed by the company's subsidiary Sichuan Guangda Pharmaceutical Manufacturing, it is the first product of its kind approved for marketing in China.

The drugmaker said the approval is not expected to have a material impact on its operating results in the near term.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10